# Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder

> **NCT01585207** · PHASE1,PHASE2 · COMPLETED · sponsor: **Barbara J. Coffey** · enrollment: 4 (actual)

## Conditions studied

- Tourette's Disorder

## Interventions

- **DRUG:** vigabatrin

## Key facts

- **NCT ID:** NCT01585207
- **Lead sponsor:** Barbara J. Coffey
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-01-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01585207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01585207, "Proof-of-Concept Safety Study of CPP-109 (Vigabatrin) for Treatment Refractory Tourette's Disorder". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01585207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*